Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Sep 15:14:266.
doi: 10.1186/s12967-016-0982-x.

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease

Xinxia Chang  1   2 , Zhe Wang  3 , Jinlan Zhang  3 , Hongmei Yan  1   2 , Hua Bian  1   2 , Mingfeng Xia  1   2 , Huandong Lin  1   2 , Jiandong Jiang  4 , Xin Gao  5   6
Affiliations
Randomized Controlled Trial

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease

Xinxia Chang et al. J Transl Med. .

Abstract

Background: We recently demonstrated a positive effect of berberine on nonalcoholic fatty liver disease patients after 16 weeks of treatment by comparing mere lifestyle intervention in type 2 diabetes patients with berberine treatment, which decreased the content of hepatic fat. However, the potential mechanisms of the clinical effects are unclear. We used a lipidomic approach to characterize the state of lipid metabolism as reflected in the circulation of subjects with nonalcoholic fatty liver disease (NAFLD) before and after berberine treatment.

Methods: Liquid chromatography-mass spectrometry evaluated the various lipid metabolites in serum samples obtained from the participants (41 patients in the berberine group and 39 patients in the mere lifestyle intervention group) before and after treatment.

Results: A total of 256 serum lipid molecular species were identified and quantified. Both treatments regulated various types of lipids in metabolic pathways, such as free fatty acids, phosphoglycerides and glycerides, in metabolic pathways, but berberine induced a substantially greater change in serum lipid species compared with mere lifestyle intervention after treatment. Berberine also caused obvious differences on ceramides. Berberine treatment markedly decreased serum levels of ceramide and ceramide-1-phosphate.

Conclusions: Berberine altered circulating ceramides, which may underlie the improvement in fatty liver disease. ClinicalTrials.gov NCT00633282, Registered March 3, 2008.

Keywords: Berberine; Ceramide; Lipidomic approach; Nonalcoholic fatty liver disease; Sphingolipids.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Lipid metabolic pathways and the regulation of berberine on the patients with IGR/Type 2 diabetes and nonalcoholic fatty liver disease
Fig. 2
Fig. 2
In order to further study the subtle differences between groups, orthogonal partial least squares discriminant analysis (OPLS-DA) was employed. This figure was the score plots obtained from OPLS-DA
See this image and copyright information in PMC

References

    1. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–717. doi: 10.1016/j.metabol.2008.01.013. - DOI - PMC - PubMed
    1. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–1351. doi: 10.1038/nm1135. - DOI - PubMed
    1. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 2009;200:159–165. doi: 10.1677/JOE-08-0419. - DOI - PubMed
    1. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1—plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885–28895. doi: 10.1074/jbc.M109.052407. - DOI - PMC - PubMed
    1. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2cells. Atherosclerosis. 2008;201:266–273. doi: 10.1016/j.atherosclerosis.2008.02.004. - DOI - PubMed

Publication types

MeSH terms

Associated data